FY2024 EPS Estimates for uniQure Lowered by Leerink Partnrs

uniQure (NASDAQ:QURE) – Research analysts at Leerink Partnrs dropped their FY2024 earnings per share estimates for shares of uniQure in a report issued on Tuesday, December 10th. Leerink Partnrs analyst J. Schwartz now forecasts that the biotechnology company will earn ($2.39) per share for the year, down from their previous estimate of ($2.28). The consensus estimate for uniQure’s current full-year earnings is ($3.81) per share. Leerink Partnrs also issued estimates for uniQure’s Q4 2024 earnings at $1.14 EPS, Q1 2025 earnings at ($1.07) EPS, Q2 2025 earnings at ($1.27) EPS, Q3 2025 earnings at ($1.53) EPS, Q4 2025 earnings at $0.21 EPS, FY2025 earnings at ($3.66) EPS and FY2026 earnings at ($1.08) EPS.

uniQure (NASDAQ:QURE) last announced its earnings results on Tuesday, November 5th. The biotechnology company reported ($0.91) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.12) by $0.21. The company had revenue of $2.29 million for the quarter, compared to analyst estimates of $2.73 million. uniQure had a negative return on equity of 188.82% and a negative net margin of 837.80%.

Other analysts have also issued research reports about the stock. HC Wainwright reiterated a “buy” rating and issued a $25.00 price objective on shares of uniQure in a research note on Tuesday, December 10th. Raymond James raised uniQure from an “outperform” rating to a “strong-buy” rating and boosted their price target for the company from $20.00 to $52.00 in a report on Tuesday, December 10th. The Goldman Sachs Group boosted their target price on shares of uniQure from $9.00 to $20.00 and gave the company a “neutral” rating in a research note on Thursday. Guggenheim reaffirmed a “buy” rating on shares of uniQure in a report on Wednesday. Finally, Royal Bank of Canada boosted their target price on shares of uniQure from $14.00 to $20.00 and gave the stock an “outperform” rating in a research note on Wednesday. One analyst has rated the stock with a sell rating, two have assigned a hold rating, five have assigned a buy rating and two have given a strong buy rating to the stock. According to MarketBeat, uniQure currently has a consensus rating of “Moderate Buy” and a consensus price target of $32.14.

uniQure Stock Performance

QURE opened at $15.40 on Friday. The company has a market cap of $750.60 million, a P/E ratio of -3.10 and a beta of 0.89. uniQure has a 52-week low of $3.73 and a 52-week high of $17.39. The company has a quick ratio of 6.51, a current ratio of 6.51 and a debt-to-equity ratio of 0.92. The firm’s 50-day moving average price is $7.04 and its 200-day moving average price is $6.36.

Institutional Investors Weigh In On uniQure

A number of hedge funds have recently added to or reduced their stakes in the business. abrdn plc lifted its holdings in shares of uniQure by 381.7% in the 3rd quarter. abrdn plc now owns 1,929,061 shares of the biotechnology company’s stock valued at $9,510,000 after purchasing an additional 1,528,581 shares during the last quarter. Franklin Resources Inc. acquired a new position in uniQure in the third quarter valued at $7,360,000. Point72 Asset Management L.P. raised its holdings in shares of uniQure by 336.1% in the third quarter. Point72 Asset Management L.P. now owns 976,893 shares of the biotechnology company’s stock valued at $4,816,000 after buying an additional 752,889 shares during the last quarter. FMR LLC boosted its stake in shares of uniQure by 8,056.6% during the third quarter. FMR LLC now owns 350,572 shares of the biotechnology company’s stock worth $1,728,000 after buying an additional 346,274 shares during the period. Finally, Assenagon Asset Management S.A. acquired a new stake in uniQure during the 2nd quarter worth approximately $815,000. 78.83% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In related news, CEO Matthew C. Kapusta sold 3,418 shares of the firm’s stock in a transaction dated Monday, December 9th. The stock was sold at an average price of $7.63, for a total transaction of $26,079.34. Following the completion of the transaction, the chief executive officer now directly owns 597,915 shares in the company, valued at $4,562,091.45. This trade represents a 0.57 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. 4.74% of the stock is currently owned by insiders.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.